Literature DB >> 11063161

Detection of Epstein-Barr virus DNA in hepatocellular carcinoma tissues from hepatitis C-positive patients.

Y Sugawara1, M Makuuchi, K Takada.   

Abstract

BACKGROUND: We have previously shown that hepatitis C virus (HCV) replication is promoted by the Epstein-Barr virus (EBV) in vitro. The aim of this study was to examine the EBV load in hepatocellular carcinoma (HCC) tissues from HCV antibody-positive patients.
METHODS: DNA was extracted from paraffin sections from 168 HCC patients. After amplification of a region in the EBV BamHI W sequence by means of the polymerase chain reaction (PCR), it was detected by Southern hybridization and semi-quantified. Ten hyperplastic lesions from HCV-positive patients and 35 non-tumorous samples from hepatitis-negative patients served as controls. The PCR results were analyzed on the basis of the patient's hepatitis status. Univariate and multivariate analyses were performed to identify clinicopathologic factors for predicting EBV infection in HCC tissues.
RESULTS: More than one copy of EBV DNA per 100 cells was detected in 56 (33%) of the HCC sections. The detection ratio in HCC tissues from HCV antibody-positive patients was 40% (45 of 113), which was significantly higher than that in tissues from HBV surface antigen-positive patients (14%, 5 of 37; P = 0.0018). The patient's serum HBV surface antigen and HCV antibody independently predicted the EBV positivity of HCC tissues.
CONCLUSIONS: These results support our hypothesis that EBV could play an important role in the development of HCV-related HCC.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11063161     DOI: 10.1080/003655200750023075

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  11 in total

1.  No direct role for Epstein-Barr virus in American hepatocellular carcinoma.

Authors:  P G Chu; Y Y Chen; W Chen; L M Weiss
Journal:  Am J Pathol       Date:  2001-10       Impact factor: 4.307

2.  Altered expression of AT-rich interactive domain 1A in hepatocellular carcinoma.

Authors:  Hiroyuki Abe; Akimasa Hayashi; Akiko Kunita; Yoshihiro Sakamoto; Kiyoshi Hasegawa; Junji Shibahara; Norihiro Kokudo; Masashi Fukayama
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

3.  Epstein-Barr virus in hepatocellular carcinogenesis.

Authors:  Wei Li; Bao-An Wu; Yong-Ming Zeng; Guang-Can Chen; Xin-Xin Li; Jun-Tian Chen; Yu-Wen Guo; Man-Hong Li; Yi Zeng
Journal:  World J Gastroenterol       Date:  2004-12-01       Impact factor: 5.742

4.  Chronic Epstein-Barr virus-related hepatitis in immunocompetent patients.

Authors:  Mihaela Petrova; Maria Muhtarova; Maria Nikolova; Svetoslav Magaev; Hristo Taskov; Diana Nikolovska; Zahariy Krastev
Journal:  World J Gastroenterol       Date:  2006-09-21       Impact factor: 5.742

Review 5.  Epstein-Barr virus: silent companion or causative agent of chronic liver disease?

Authors:  Mihaela Petrova; Victor Kamburov
Journal:  World J Gastroenterol       Date:  2010-09-07       Impact factor: 5.742

6.  (-)-Epigallocatechin-3-gallate inhibition of Epstein-Barr virus spontaneous lytic infection involves downregulation of latent membrane protein 1.

Authors:  Sufang Liu; Hongde Li; Min Tang; Ya Cao
Journal:  Exp Ther Med       Date:  2017-11-13       Impact factor: 2.447

7.  Use of adenovirus vectors expressing Epstein-Barr virus (EBV) immediate-early protein BZLF1 or BRLF1 to treat EBV-positive tumors.

Authors:  Wen-hai Feng; Eva Westphal; Amy Mauser; Nancy Raab-Traub; Margaret L Gulley; Pierre Busson; Shannon C Kenney
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

8.  Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas.

Authors:  Wen-hai Feng; Gregory Hong; Henri-Jacques Delecluse; Shannon C Kenney
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

9.  New cellular tools reveal complex epithelial-mesenchymal interactions in hepatocarcinogenesis.

Authors:  S Sagmeister; M Eisenbauer; C Pirker; T Mohr; K Holzmann; H Zwickl; C Bichler; D Kandioler; F Wrba; W Mikulits; C Gerner; M Shehata; O Majdic; B Streubel; W Berger; M Micksche; K Zatloukal; R Schulte-Hermann; B Grasl-Kraupp
Journal:  Br J Cancer       Date:  2008-07-08       Impact factor: 7.640

Review 10.  Lipoxins: nature's way to resolve inflammation.

Authors:  Jayashree A Chandrasekharan; Neelam Sharma-Walia
Journal:  J Inflamm Res       Date:  2015-09-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.